medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-129Research ArticleСтатьиПоражение сердца при артериальной гипертонии. Лекарственные методы воздействия на гипертензию и сократительную дисфункциюCardiac involvement in hypertension. Medicinal methods of influence on hypertension and contractile dysfunctionГуревичМ. А.GurevichM. A.noemail@neicon.ruГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»РоссияMoscow Regional Scientific and Research Clinical Institute n.a. M.F. VladimirskyRussian Federation201728042017113Кардиология3538Copyright © Гуревич М.А., 20172017Гуревич М.А.Gurevich M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/129

В обзоре на основании данных литературы и многолетних собственных представлений подробно описаны современные сведения о поражении сердечно-сосудистой системы при гипертонической болезни. Обосновано клиническое и прогностическое значение гипертрофии ЛЖ при АГ на основании данных Эхо-КГ и ЭКГ. Прогрессирование АГ у пожилых значительно осложняется сопутствующими заболеваниями: ИБС, СД, ГЛЖ и др. Терапия больных АГ, кроме снижения АД, требует уменьшения ММ ЛЖ, профилактики ХСН. Патогенетическое значение имеют препараты, снижающие активность ренин-ангиотензин-альдостероновой системы (РААС): иАПФ, сартаны.

The review on the basis of literature data and own long-term views describes in detail current data on the defeat of the cardiovascular system in hypertension. The clinical and prognostic significance of left ventricular hypertrophy in arterial hypertension based on echocardiographic data and ECG is substantiated. The progression of hypertension in the elderly is considerably complicated by concomitant diseases: coronary heart disease, diabetes, left ventricular hypertrophy etc. Therapy of patients with hypertension in addition to lowering blood pressure requires a reduction of the mass of the left ventricular myocardium, for the prevention of chronic heart failure. Drugs that reduce the activity of the renin-angiotensin-aldosterone system - ACE-I, sartans - have pathogenetic importance.

артериальная гипертониягипертрофия левого желудочкадисфункция миокардасердечная недостаточностьиАПФсартаныдиуретикиarterial hypertensionleft ventricular hypertrophymyocardial dysfunctionheart failureACE-IsartansdiureticsReferencesBrown D. W., Giles W. H., Croft J. B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am. Heart J. 2000 Dec; 140 (6): 848-56.Brown D. W., Giles W. H., Croft J. B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am. Heart J. 2000 Dec; 140 (6): 848-56.Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann. Intern. Med. 1989 Jan 15; 110 (2): 101-7.Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann. Intern. Med. 1989 Jan 15; 110 (2): 101-7.Verdecchia P., Porcellati C., Reboldi G., Gattobigio R., Borgioni C., Pearson T. A., Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001 Oct 23; 104 (17): 2039-44.Verdecchia P., Porcellati C., Reboldi G., Gattobigio R., Borgioni C., Pearson T. A., Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001 Oct 23; 104 (17): 2039-44.Danlof B., Devereux R. B., Kieldsen S. E., et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Danlof B., Devereux R. B., Kieldsen S. E., et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Olsen M. H., Wachtell K., Hermann K. L., Frandsen E., Dige-Petersen H., Rokkedal J., Devereux R. B., Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am. Heart J. 2002 Sep; 144 (3): 530-7.Olsen M. H., Wachtell K., Hermann K. L., Frandsen E., Dige-Petersen H., Rokkedal J., Devereux R. B., Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am. Heart J. 2002 Sep; 144 (3): 530-7.Post W. S., Larson M. G., Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation. 1994 Jul; 90 (1): 179-85.Post W. S., Larson M. G., Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation. 1994 Jul; 90 (1): 179-85.Appel L. J., Stason W. B. Ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and management of hypertension. Ann. Intern. Med. 1993 Jun 1; 118 (11): 867-82.Appel L. J., Stason W. B. Ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and management of hypertension. Ann. Intern. Med. 1993 Jun 1; 118 (11): 867-82.Wachtell K., Dahlöf B., Rokkedal J., Papademetriou V., Nieminen M. S., Smith G., Gerdts E., Boman K., Bella J. N., Devereux R. B. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am. Heart J. 2002 Dec; 144 (6): 1057-64.Wachtell K., Dahlöf B., Rokkedal J., Papademetriou V., Nieminen M. S., Smith G., Gerdts E., Boman K., Bella J. N., Devereux R. B. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am. Heart J. 2002 Dec; 144 (6): 1057-64.Devereux R. B., Alonso D. R., Lutas E. M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiology. 1986; 57: 450-8.Devereux R. B., Alonso D. R., Lutas E. M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiology. 1986; 57: 450-8.Kannel W. B., Belanger A. J. Epidemiology of heart failure. Am. Heart J. 1991 Mar, 121 (3 Pt 1): 951-7.Kannel W. B., Belanger A. J. Epidemiology of heart failure. Am. Heart J. 1991 Mar, 121 (3 Pt 1): 951-7.Кушаковский М. С. Гипертоническая болезнь. СПб.: Гиппократ, 1995.- 312 с.Кушаковский М. С. Гипертоническая болезнь. СПб.: Гиппократ, 1995.- 312 с.Levy D., Larson M. G., Vasan R. S., Kannel W. B., Ho K. K. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29; 275 (20): 1557-62.Levy D., Larson M. G., Vasan R. S., Kannel W. B., Ho K. K. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29; 275 (20): 1557-62.Гогин Е. Е. Гипертоническая болезнь. - М., 1997.- 399 с.Гогин Е. Е. Гипертоническая болезнь. - М., 1997.- 399 с.European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003 Jun; 21 (6): 1011-53.European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003 Jun; 21 (6): 1011-53.Sica D. A., Weber M. The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age? J. Clin. Hypertens (Greenwich). 2002 Jul-Aug; 4 (4): 301-5.Sica D. A., Weber M. The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age? J. Clin. Hypertens (Greenwich). 2002 Jul-Aug; 4 (4): 301-5.De Luca N., Safar M. E. Efficacy of a very-low-dose perindopril 2 mg / indapamide 0,625 mg on cardiac hypertrophy in hypertensive patients. J. Hypertens 2002; 20 (4).De Luca N., Safar M. E. Efficacy of a very-low-dose perindopril 2 mg / indapamide 0,625 mg on cardiac hypertrophy in hypertensive patients. J. Hypertens 2002; 20 (4).Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.

The authors declare that there are no conflicts of interest present.